Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Nivolumab in Advanced NSCLC
NCT04211896Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04211896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211896.